medigraphic.com

2006, Number 2

<< Back Next >>

Rev Med Hosp Gen Mex 2006; 69 (2)

Clinical and epidemiologic characteristics of Bell's palsy in the Rehabilitation and Special Education Center of Durango, Mexico

Aboytes-Meléndez CA, Torres-Valenzuela A

Language: Spanish
References: 20
Page: 70-77
PDF size: 125.35 Kb.


ABSTRACT

Objective: To identify clinic and epidemiologic features of patients with facial palsy attended at CREE Durango since 2002 through 2003. Material and methods: Descriptive design with a review of patient’s files attended at the CREE for the first time with diagnostic of facial palsy since 2002 through 2003. Statistical analysis was made with descriptive statistics using Epi-Info for Windows and inferential statistics. Results: There were 203 files analyzed. Mean age was 40 years (SD 19.7; [IC95% = 39.81,40.19]), 123 (61%; [IC95% = 54%;67%]) were women. Clinical features are similar to those reported in other papers. More than 50% attended the CREE between the first two weeks of disease and 84% ([IC95% = 79,89]) had received previous treatment. More common treatments prescribed were vitamins and prednisone (61% and 35% [IC95% = 54, 68 y 28, 41], respectively). Physiatric treatment more prescribed at the first time was electrotherapy or exercise (66% and 65% [IC95% = 57, 74 y 58, 71], respectively) although their use is controversial. 72.7% ([IC95% = 67, 79]) of patients followed until discharged got better before three months after first review. Most frequent sequelae was weakness in 33.6% ([IC95% = 25, 42]). Conclusion: There is not difference with the epidemiologic features of this paper and others. Physiatric treatments most used are electrotherapy and exercise. Desertion is high. Treatment with laser seems to be better than treatment with electrotherapy.


REFERENCES

  1. Campbell K, Brundage JF. Effects of climate, latitude and season on the incidence of Bell’s palsy in the US Armed Forces, October 1997 to September 1999. Am J Epidemiol 2002; 156 (1): 32-39.

  2. Rowlands S, Hooper R, Hughes R, Burney P. The epidemiology and treatment of Bell’s palsy in the UK. Eur J Neurol 2002; 9 (1): 63-67.

  3. Rodríguez-Blano A, Morera-Montes J. Aciclovir en el tratamiento de la parálisis facial idiopática. Medefam 2003; 311-313.

  4. González-Cano LL, Sánchez-Ortiz AO, Pérez-Benítez ML. Estandarización de la onda F del nervio facial y su valor pronóstico en la parálisis facial. Rev Mex Med Fis Rehab 2001; 13 (4): 113-115.

  5. Jorba-Basave S, Peñalosa-González JM, González-Sánchez DF et al. Parálisis facial. Rev Hosp Dr M Gea Gonz 2001; 4 (1-2): 21-26.

  6. Abiko Y, Ikeda M, Hondo R. Secretion and dynamics of herpes simplex virus in tears and saliva of patients with Bell’s palsy. Otol Neurotol 2002; 23 (5): 779-783.

  7. Navarrete MC, Céspedes R, Mesa M, Grasa J, Pérez M, Raguer N et al. Parálisis facial de Bell recurrente: Nuestra experiencia. Acta Otorrinolaringol Esp 2001; 52: 682-686.

  8. Montes-Dorantes G, Vales-Hidalgo O, Pane-Pianese C, Rembao-Bojórquez D. Determinación de virus del herpes simple tipo I en pacientes con parálisis facial periférica idiopática y respuesta al tratamiento con antivirales y esteroides. Arch Neurocienc 2002; 7 (2): 76-82.

  9. Aboytes-Meléndez CA, Torres-Valenzuela A. Estudio epidemiológico de parálisis facial en el Centro de Rehabilitación y Educación Especial (CREE) Durango. Reporte preliminar. La Salud en Durango 2004; 5 (2): 19-23.

  10. Domínguez-Carrillo LG. Zonas anatómicas de lesión en parálisis facial periférica y su relación etiológica. Experiencia de 780 casos. Cir Cir 2002; 70: 239-245.

  11. Scola-Yurrita B, Ramírez-Calvo C, Scola-Plego E. Parálisis facial recidivante idiopática. Acta Otorrinolaringol Esp 2004; 55: 343-345.

  12. Yetiser S, Sator B, Kazyakasi M. Immunologic abnormalities and surgical experiences in recurrent facial nerve paralysis. Otol Neurotol 2002; 772-778.

  13. Salinas RA, Álvarez G, Álvarez M, Ferreira J. Tratamiento con corticosteroides para la parálisis de Bell (parálisis facial idiopática) (Revisión Cochrane traducida). En: La Cochrane Library plus en español, número 3, 2004. Oxford: Update Software, Ltd.

  14. Shannon S, Meadows S, Horwitz S. Are drug therapies effective in treating Bell’s palsy? J Fam Pract 2003; 52 (2): 156-159.

  15. Buttress S. Electrical stimulation and Bell’s palsy. Emerg Med J 2002; 19 (5): 428.

  16. Flores-Flores P, Medina-Zazueta R, Haro-García L. Tratamiento de la parálisis facial periférica idiopática: terapia física versus prednisona. Rev Med IMSS 1998; 36 (3): 217-221.

  17. Chevalier AM. Rehabilitación de las parálisis faciales centrales y periféricas. Encicl Med Chir (Elsevier, Paris-Francia), Kinesiterapia-Medicina Física-Rehabilitación, 26-463-B10, 1990, 16p.

  18. Rioja-Toro J. Nueva sistematización del tratamiento de la parálisis facial periférica. Rehabilitación 1993; 27 (4): 276-284.

  19. Monje MS, Vallalón RV. Parálisis facial periférica y terapia física: Puesta al día. Rev Kinesiol 2002; 68 (Accesado vía electrónica el 12 de junio de 2003 en: http: www. colkinechile.cl/arch/revista/cont.68html).

  20. Choi D, Raisman G. Somatotopic organization of the facial nucleus is disrupted after lesioning and regeneration of the facial nerve. The histological representation of synkinesis. Neurosurgery 2002; 50 (2): 355-63.




2020     |     www.medigraphic.com